Victory Capital Management
QNCX icon

Victory Capital Management’s Quince Therapeutics QNCX Stock Holding History

Victory Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-65
Closed -$468K – 2802
2021
Q1 		$468K Buy
65
+1
+2% +$7.2K ﹤0.01% 2236
2020
Q4 		$358K Buy
64
+4
+7% +$35.4K ﹤0.01% 2220
2020
Q3 		$595K Sell
60
-19
-24% -$173K ﹤0.01% 1897
2020
Q2 		$727K Buy
79
+63
+394% +$577K ﹤0.01% 1865
2020
Q1 		$148K Buy
+16
New +$158K ﹤0.01% 2416
2019
Q4 		– Sell
-4
Closed -$20K – 3120
2019
Q3 		$20K Buy
+4
New +$24.6K ﹤0.01% 3048

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Victory Capital Management's QNCX Position: Q2 2021 in Review

Victory Capital Management sold out of Quince Therapeutics (QNCX) in Q2 2021, closing a stake of 65 shares — an estimated $468K sold.

Victory Capital Management first reported a position in QNCX in Q3 2019 and held it in 6 quarters. The position peaked at $727K in Q2 2020. 100 funds tracked by Wall St. Rank hold QNCX as of Q2 2021.

  • Victory Capital Management reported no remaining Quince Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Victory Capital Management sold 65 Quince Therapeutics shares in Q2 2021, an estimated $468K.
  • Victory Capital Management first reported a position in Quince Therapeutics in Q3 2019 and held it in 6 quarters.
  • Victory Capital Management's Quince Therapeutics position peaked at $727K in Q2 2020.
  • 100 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2021.

Based on Victory Capital Management's 13F filing for Q2 2021, filed 3 Aug 2021.